Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
2(50%)
Results Posted
100%(1 trials)
Terminated
1(25%)

Phase Distribution

Ph phase_1
1
25%
Ph phase_2
3
75%

Phase Distribution

1

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
3(75.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

2

trials recruiting

Total Trials

4

all time

Status Distribution
Active(2)
Completed(1)
Terminated(1)

Detailed Status

Active, not recruiting2
Completed1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
2
Success Rate
50.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (25.0%)
Phase 23 (75.0%)

Trials by Status

active_not_recruiting250%
completed125%
terminated125%

Recent Activity

2 active trials
Showing 4 of 4
active_not_recruitingphase_2

A Phase II Study of Venetoclax in Combination With Dose-adjusted EPOCH-R or R-CHOP for Patients With Richter's Syndrome

NCT03054896
active_not_recruitingphase_2

Biomarker Driven Intensified ChemoImmunotherapy With Early CNS Prophylaxis

NCT03293173
completedphase_1

Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma

NCT02142049
terminatedphase_2

Dose-adjusted EPOCH-R in MYC Positive DLBCL

NCT01914718

Clinical Trials (4)

Showing 4 of 4 trials
NCT03054896Phase 2

A Phase II Study of Venetoclax in Combination With Dose-adjusted EPOCH-R or R-CHOP for Patients With Richter's Syndrome

Active Not Recruiting
NCT03293173Phase 2

Biomarker Driven Intensified ChemoImmunotherapy With Early CNS Prophylaxis

Active Not Recruiting
NCT02142049Phase 1

Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Completed
NCT01914718Phase 2

Dose-adjusted EPOCH-R in MYC Positive DLBCL

Terminated

All 4 trials loaded

Drug Details

Intervention Type
COMBINATION PRODUCT
Total Trials
4